Molecular Genetic Markers in Female Reproductive Cancers
1Departments of Gynecology and Obstetrics and Oncology, and Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
2Department of Pathology, Norwegian Radium Hospital, Rikshospitalet University Hospital, Montebello, 0310 Oslo, Norway
3Departments of Pathology and Microbiology and Immunology, The University of South Carolina School of Medicine, Columbia, SC 29203, USA
4Department of Medicine, National Taiwan University, Taipei 10617, Taiwan
5Center for Hematology and Oncology, Department of Internal Medicine I, Wilhelminenspital, 1160 Vienna, Austria
Molecular Genetic Markers in Female Reproductive Cancers
Description
Cancer is a complex genetic disease as a result of accumulated genomic alterations which serve as the driving force in initiating tumor development and propelling tumor progression. The Darwinian evolution theory of cancer predicts that clinically detectable tumors harbor the molecular genetic changes that are causally related to uncontrolled growth, survival in dynamic microenvironment, invasion into surrounding normal tissues, and metastasis to distant organs. Various forms of genomic abnormalities have occurred in cancers, such as point mutations, DNA copy number alterations, and chromosomal rearrangements. Proto-oncogenes are typically activated by gene amplifications, gene translocations, and activating intragenic mutations, whereas tumor suppressors are inactivated by gene deletions (loss of heterozygosity or homologous deletion), inactivating intragenic mutations, and epigenetic silencing. Recent advances in molecular genomic technology and the success of human genome project have empowered investigators with new tools in analyzing cancer genome in great details and have expedited the discovery of new cancer-associated genes. Decoding the genetic history present in tumor DNA, as well as identification and characterization of molecular changes involving cancer-associated genes and the pathways they controlled, has not only shed new light on the molecular etiology of cancer, but also has promised for the development of new diagnostic markers and novel therapeutics.
In this special issue, we invite authors to present original research articles as well as timely reviews that will stimulate the continuing efforts in identifying and characterizing new biomarkers and therapeutic targets in female reproductive cancers including breast, ovarian, endometrial, and cervical cancer. Studies that evaluate mutations, bioinformatics for genome-wide data analysis, biomarkers to predict prognosis and treatment outcome, as well as preclinical and clinical studies in new therapeutic development are particularly welcome. Translational studies that focus on assessing the clinical significance of expression of biomarkers are also encouraged.
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jo/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: